Disease Area

Research Area

Colorectal cancer / ICD-10: C18.0

Colorectal cancer, survival prediction, artificial Intelligence, etc.

Sample Types

• H&E stained FFPE tissue slides (RT storage)
• Immunohistochemistry (IHC) on FFPE tissue slides (RT storage)
• Whole slide images of H&E and IHC FFPE tissue slides

Cohort Size

• Over 180 000 images (resolution 0.25µm/pixel, over 800 TByte)
• from 100 000 slides (H&E and IHC staining of FFPE tissue sections)
• from over 6 400 cases
• comprising tissue from colorectal cancer resections (tumour and non-tumour colon tissue, resection margins, fatty tissue, and associated lymph nodes)

Donors

Inclusion criteria:

Patients with colorectal cancer as a primary diagnosis (C18), samples from 1984 to 2013

• Patient age: 18 – 100 years
• Tumour stages: II to III
• Ratio female : male = 45:55

Associated Data*

• Pathology diagnosis
• TNM staging
• ICD-10 and ICD-O codes
• Survival data
• Meta data from whole slide images

Informed Consent

Depending on year of collection with or without informed consent

Access

Access for collaborative research projects depending on ethics committee  approval of Medical University of Graz

Quality Standards

ISO 9001:2015 (Biobank Graz)

Contact

Univ.-Prof. Dr. med. univ. Kurt Zatloukal

Email: kurt.zatloukal@medunigraz.at                        

Disease Area

Research Area

Colorectal cancer / ICD-10: C18.0

Colorectal cancer, inflammation, artificial Intelligence, etc.

Sample Types

• H&E stained FFPE tissue slides (RT storage)
• (Immuno)histochemistry (IHC) on FFPE tissue slides, Elastica van Giesson staining, vascular endothelial marker IHC (CD-31) (RT storage)
• Whole slide images of H&E and IHC FFPE tissue slides

Cohort Size

• Approx. 800 whole slide images (resolution 0.25µm/pixel)
• from ~ 800 slides (H&E, histochemical and IHC staining of FFPE tissue sections)
• from over 260 cases
• comprising colorectal tumour tissue

Donors

Inclusion criteria:

Patients with colorectal cancer as a primary diagnosis (C18), samples from 1984 to 2013

• Age: 18 – 100 years
• Stages: I to IV
• Female, male

Associated Data*

• Pathology diagnosis
• TNM staging
• ICD-10 and ICD-O codes
• Clinical data*
• Survival data
• Meta data from whole slide images

     *see details about associated data below

Informed Consent

Depending on year of collection with or without informed consent

Access

Access for collaborative research projects depending on ethics committee  approval of Medical University of Graz

Quality Standards

ISO 9001:2015 (Biobank Graz)

Contact

Univ.-Prof. Dr. med. univ. Kurt Zatloukal

Email: kurt.zatloukal@medunigraz.at                       

Disease Area

Research Area

Colorectal cancer / ICD-10: C18.0

Colorectal cancer, artificial Intelligence, etc.

Sample Types

• H&E stained FFPE tissue slides (RT storage)
• Immunohistochemistry (IHC) on FFPE tissue slides (RT storage)
• Whole slide images of H&E and IHC FFPE tissue slides

Cohort Size

• Approx. 1800 whole slide images (resolution 0.25µm/pixel)
• from ~ 800 slides (H&E and IHC staining of FFPE tissue sections)
• from over 100 cases
• comprising tissue from colorectal cancer resections (tumour and non-tumour colon tissue, resection margins, fatty tissue, and associated lymph nodes)

Donors

Inclusion criteria:

Patients with colorectal cancer as a primary diagnosis (C18), samples from 1984 to 2013

• Age: 18 – 100 years
• Stages: II and III
• Female, male

Associated Data*

• Pathology diagnosis
• TNM staging
• ICD-10 and ICD-O codes
• Clinical data*
• Survival data
• Meta data from whole slide images

*see details about associated data below

Informed Consent

Depending on year of collection with or without informed consent

Access

Access for collaborative research projects depending on ethics committee  approval of Medical University of Graz

Quality Standards

ISO 9001:2015 (Biobank Graz)

Contact

Univ.-Prof. Dr. med. univ. Kurt Zatloukal

Email: kurt.zatloukal@medunigraz.at                        

The "CoVVac Study " is a sample collection at Biobank Graz (Med Uni Graz) which is based on a prospective sample cohort for current research on immune response to COVID-19 vaccines in immunocompromised and healthy individuals.

Study design:

This study will characterize and analyze the anit-SARS-CoV-2 humoral and cellular immune response before and after vaccination with a focus on the anti-spike protein response in immunocompromised patients compared to healthy controls. Participants are invited to five visits where samples are collected and one telephone interview:

• 1^st visit (60-0 days before vaccination)
• 2^nd "visit" is a telephone interview to get information on vaccine reactions.
• 3^rd visit (+21-28 days after 2^nd vaccination)
• 4^th visit (+ 6 months after 2^nd vaccination)
• 5^th visit (+3-6 weeks after visit 4 or 3^rd vaccination)
• 6^th visit (+6 months after visit 4)

Disease Area

Research Area

  COVID-19 recovered patients, SARS-CoV-2, PCR test, antibody test

Sample Types

  serum, EDTA buffy coat, EDTA plasma, lithium heparin plasma, sodium citrate  

  plasma, saliva and nasopharyngeal swabs (stored at -80 °C)

Cohort Size

  23.739 aliquots from 364 participants as of March 10^th  

Donors

  volunteers who recovered from COVID-19

• Sub cohort I: Persons who were officially tested positive for an infection by PCR test with the SARS-CoV-2 virus, showed symptoms of COVID-19 and recovered. (342 participants)

• Sub cohort II: (22 participants)

1. Persons who lived together or got in contact with a person officially tested positive by PCR test for SARS-CoV-2 and showed symptoms of COVID-19 disease within 14 days, but were not tested themselves, and recovered.

2. Persons who showed leading COVID-19 symptoms (fever, dry cough, loss of smell or taste, diarrhoea, fatigue) since December 2019, but were not tested themselves, independent of whether they had contact to a person positive tested for SARS-CoV-2, and recovered.

Associated Data

  Data concerning symptoms, comorbidities, prehistory and lifestyle

  are collected via questionnaire

PCR tests and  antibody tests are performed

Informed Consent

  Broad Biobank IC (view template de>>; view template en>>), sStudy specific IC

Access

  As of now

Quality Standards

• Quality management: ISO 9001:2015 (SOPs)

• CEN/TS 16945:2016 (metabolomics in urine, venous blood serum and plasma)

Contact

Publications

• Principle investigator: Univ.-Prof. Dr. med. univ. Robert Krause

• Email: biobank-pm@medunigraz.at       

Kral S, Banfi C, Niedrist T, Sareban N, Guelly C, Kriegl L, Schiffmann S, Zurl C, Herrmann M, Steinmetz I, Schlenke P, Berghold A, Krause R. Long-lasting immune response to a mild course of PCR-confirmed SARS-CoV-2 infection: A cohort study. J Infect. 2021 Nov;83(5):607-635. doi:

Niedrist T, Drexler C, Torreiter PP, Matejka J, Strahlhofer-Augsten M, Kral S, Riegler S, Gülly C, Zurl C, Kriegl L, Krause R, Berghold A, Steinmetz I, Schlenke P, Herrmann M. Longitudinal comparison of automated SARS-CoV-2 serology assays in assessing virus neutralization capacity in COVID-19 convalescent sera. Arch Pathol Lab Med. 2022 Jan 27. doi: 10.5858/arpa.2021-0604-SA. Epub ahead of print. PMID: 35085385

Eva M. Matzhold, Günther F. Körmöczi, Chiara Banfi, Marlies Schönbacher, Camilla Drexler, Helmberg, Ivo Steinmetz, Andrea Berghold, Peter Schlenke, Gabriel E. Wagner,
Anja Stoisser, Barbara Kleinhappl, Wolfgang R. Mayr and Thomas Wagner. Lower Levels of ABO Anti-A and Anti-B of IgM, IgG and IgA Isotypes in the Serum but Not the Saliva of COVID-19 Convalescents. J. Clin. Med. 2022, 11(15), 4513 doi.org/10.3390/jcm11154513

Disease Area/

Research Area

Lymphoma in cats

Sample Types

Fixed and native samples from tumor and healthy reference tissues (FFPE, glutaraldehyde for electron microscopy, OCT, RNAlater, pure), serum, plasma, urine, feces;

Cohort Size

• Complete set of samples and data with follow up examination for 36 patients available;
• Collection start February 2016 - collection ongoing

Donors

• untreated, treated
• age
• gender

Associated Data

Clinical data (anamnesis, treatment: medication, surgical intervention, laboratory results, imaging data..), sample management data, images from HE-stains;

Informed Consent

Approved by the patient owner

Access to

• Internal academic research,
• external academic research,
• industrial research - cooperation preferred

Quality Standards

 Tissue samples were collected according to the sample pre-analytics standards:  CEN/TS 16826 1-2, CEN/TS 16827  1-3;

Contact

Sample Coordinator: VetBiobank, Ingrid Walter
Email: Ingrid.Walter@vetmeduni.ac.at

Principle investigator: Birgitt Wolfesberger

Email: Birgitt.Wolfesberger@vetmeduni.ac.at

Disease Area

Research Area

Intermittent fasting, alternate day fasting (ADF), effects on autophagy, human physiology, aging process and molecular-cellular processes

Sample Types

Serum, plasma and urine samples stored at -80°C

Cohort Size

 90 donors:

• 30 subjects cohort - 2 study visits

• 60 subjects RCT - 4 study visits

Donors

Cohort (Alternate day fasting for at least 6 months before the start of the trial – 30 subjects) as well as randomized control-trial (60 subjects – randomized to either intervention group (alternate day fasting) or control group with no intervention 1:1).

Adults 35 - 65 years; ratio female:male = 57:43

Further inclusion criteria:

• Body mass index in the range of 22.0 – 30.0 kg/m2
• Fasting blood glucose <110mg/dL (without medication)
• LDL-cholesterol <180 mg/dL (without medication)
• Blood pressure <140/90 mmHg (without medication)
• Stable weight (change <± 10%) for 3 months immediately

Exclusion criteria: see INTERFAST cohort details >>

Associated Data

• Demographics
• Medical history
• Concomitant medication
• Vital signs
• Physical examination
• Blood sampling with oral glucose tolerance test (oGTT)
• Electrocardiogram (ECG)

Informed Consent

 Broad Biobank IC (view template de>>; view template en>>), specific study IC

Access

   Cooperation  preferred

Quality Standards

Quality management: ISO 9001:2015 (SOPs)

Contact

• Principle investigator: Assoc.-Prof. Dr. Harald Sourij

• Email: biobank-pm@medunigraz.at

Disease Area

Research Area

Febrile illness

Sample Types

ETDA blood (plasma, pellet and whole blood), blood in PAXgene tubes, cerebrospinal fluid, throat swab, urine, and stool stored at -80°C

Cohort Size

 Samples from 500 patients

Donors

Children <18 years

• with fever >38ºC, or a history of fever (within 3 days), in whom the attending clinician determines the need for blood sampling or whom parents give consent for bloods taken for research purposes.
• suspected of infection (included: full spectrum of disease severity, and with co-morbidities)

Associated Data

   --

Informed Consent

   Specific study IC 

Access

   Cooperation only

Quality Standards

• Quality management: ISO 9001:2015 (SOPs)

Contact

• Principle investigator:
  • Univ. Prof. Dr. Werner Zenz
  • Pediatric and Adolescent University Hospital, Department of General Pediatrics Medical University of Graz
• Email: perform@medunigraz.at, biobank-pm@medunigraz.at,

"PoCOsteo" stands for Point-of-care in-office device for identifying individuals at high risk of Osteoporosis and osteoporotic fracture.

It is being collected (starting May 2018) in the context of the HORIZON 2020 project PoCOsteo (Proposal number 767325) which aims at developing point-of-care in-vitro devices to measure and/or quantify proteomic and genomic factors in human whole blood.

The clinical cohort includes male and female patients fifty years and above and ranges from healthy (per definition) to those who experienced multiple fragility fractures due to secondary osteoporosis.

It comprises untreated patients as well as those treated for osteoporosis, with or without concomitant diseases such as hypertension, diabetes etc.

The samples meet the requirements of the sample quality standards "CEN/TC 140 Molecular in vitro diagnostic examinations - Specifications for preexamination processes (CEN/TS) for metabolomics in urine, venous blood serum and plasma" (CEN/TS 16945:2016) that were published by the European Committee for Standardization (CEN). More about sample types and quality in our BBMRI.at Catalogue >>

(C) BBMRI.at (Medical University of Graz)

Disease Area

Research Area

Endocrinology, osteoporosis, osteoporotic fractures

Biomarker development & detection

Sample Types

  Serum, EDTA-plasma and buffy coat (stored at -80°C)

Cohort Size

• 1,000 probands

• Collection start in May 2018 - collection ongoing

Donors

• Healthy and diseased, treated and untreated for osteoporosis with or without concomitant diseases (e.g. hypertension, diabetes, …)

• Age: adults > 50 years;

• Gender: female and male

Associated Data

From the following time-points: study inclusion, after 12 and possibly 24 months: bone mineral density (BMD) of the hip and the lumbar spine as well as vertebral fracture assessment (VFA) by Dual X-ray absorptiometry (DXA), grip strength (hydraulic hand dynamometer), and a routine blood test including renal and hepatic parameters together with a lipid profile

Informed Consent

   Broad Biobank IC (view template >>) & specific study IC

Access

   Cooperation preferred

Quality Standards

• Sample quality: CEN/TS 16945:2016 - Molecular in vitro diagnostic examinations. Specifications for pre-examination processes for metabolomics in urine, venous blood serum and plasma
• Quality management: ISO 9001:2015 (SOPs)

Contact

• Principle investigator: Hans Dimai, Medical University of Graz, Department of Internal Medicine, Division of Endocrinology and Metabolism

• Email: biobank-pm@medunigraz.at, hans.dimai@medunigraz.at

"BioPersMed" stands for "Biomarkers for Personalised Medicine in Common Metabolic Disorders.

This prospectively collected cohort comprises a huge number of samples and data being collected and used since 2010 (still ongoing). Aim is to detect and define specific characteristics and personalized biomarkers of patients at risk for cardiovascular and metabolic diseases and to follow them for future developments.

The "BioPersMed Cohort" includes the research areas endocrinology & metabolism and cardiology. Diabetes, fatty liver disease, osteoporosis or cardiovascular diseases are only some of the topics in the focus of this cohort.

The samples meet the requirements of the sample quality standards "CEN/TC 140 Molecular in vitro diagnostic examinations - Specifications for preexamination processes (CEN/TS) for metabolomics in urine, venous blood serum and plasma" (CEN/TS 16945:2016) that were published by the European Committee for Standardization (CEN). More about sample types and quality in the BBMRI Directory >>

(C) Bernhard Bergmann

(provided by Medical University of Graz)

Disease Area

Research Area

   Diabetes, fatty liver disease, osteoporosis, cardiovascular diseases.

   Biomarker, endocrinology,  metabolism, cardiology;

Sample Types

   Plasma (EDTA, Lithium Heparin, Sodium Citrate), serum, buffy coat

   urine, 24h urine of healthy and diseased patients

Cohort Size

• 1,024 probands (in 4 follow-up visits): healthy and diseased
• >220,000 aliquots (as per March 2018)
• collection ongoing

Donors

• Healthy and diseased,
• Age: adults 35+ years;
• Gender: 50/50 female/male

Associated Data

   Clinical records/diagnosis, smoking and lifestyle anamnesis,

   follow-up laboratory results, follow-up clinical data

   view detailed  phenotyping description (abstract) >>

Informed Consent

   Broad Biobank IC (view template >>) & specific study IC

Access

   Cooperation only

Quality Standards

• Sample quality: CEN/TS 16945:2016 - Molecular in vitro diagnostic examinations. Specifications for pre-examination processes for metabolomics in urine, venous blood serum and plasma
• Quality management: ISO 9001:2015 (SOPs)

Contact

• Scientific director: Barbara Obermayer-Pietsch
• Partners: Thomas Pieber, Karine Sargsyan, Albrecht Schmidt
• Email: biobank-pm@medunigraz.at, barbara.obermayer@medunigraz.at